Clinical trials: High Output Shock
Catecholamine-resistant Hypotension (CRH), Distributive Shock
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
This is a Phase 3, double-blind, randomized study of LJPC-501 (angiotensin II) in adult patients diagnosed with catecholamine-resistant hypotension (CRH) conducted in multiple centers globally.
- Conditions
- Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
- Trial name
- ATHOS-3 (NCT02338843)
- Testing
- LJPC-501
- Where
- 115 sites in United States, Australia and 8 more
- Volunteers
- 344 people
- Sponsor
- La Jolla Pharmaceutical Company
Catecholamine-resistant Hypotension (CRH), Distributive Shock
A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock
The objective of this study is to evaluate the effect of LJPC-501 infusion on mean arterial pressure (MAP) as assessed by standard of care vasopressor dose reduction in pediatric patients with catecholamine-resistant hypotension…
- Conditions
- Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Septic Shock
- Trial name
- NCT03623529
- Testing
- LJPC-501 (angiotensin II)
- Where
- 2 sites in Belgium, Lithuania
- Volunteers
- 100 people
- Sponsor
- La Jolla Pharmaceutical Company
Septic Shock
Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study
The investigators propose a dose finding study to determine the feasibility of Angiotensin II (AII) to increase mean arterial pressure in high-output shock.
- Trial name
- ATHOS (NCT01393782)
- Testing
- Angiotensin II
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- George Washington University
Catecholamine-resistant Hypotension (CRH), Distributive Shock
A Study of LJPC-501 in Pediatric Patients With Hypotension
The objective of this study is to evaluate the effect of LJPC-501 infusion on mean arterial pressure (MAP) or reduction in sum norepinephrine (NE) equivalent dosing, at Hour 2 after the start of LJPC-501, in pediatric patients…
- Conditions
- Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
- Trial name
- NCT03431077
- Testing
- Angiotensin II
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- La Jolla Pharmaceutical Company
Catecholamine Resistant Hypotension (CRH), Distributive Shock
Expanded Access for LJPC-501
The primary objective of the study is to provide access to LJPC-501 for distributive shock patients who remain hypotensive despite receiving fluid and vasopressor therapy.
- Conditions
- Catecholamine Resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
- Trial name
- NCT03245528
- Testing
- LJPC-501
- Sponsor
- La Jolla Pharmaceutical Company